Abstract

The selective neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was injected (IV) into monkeys ( Macaca fasicularis) in two different injection regimes. With the small dose regime, one monkey was injected with 0.25 mg/kg, every other day, over a 16 day period. In the large dose regime, another monkey was injected with 0.5 mg/kg every other day, over an 8 day period. While the time required for drug delivery was varied between animals, the total dose delivered was 2 mg/kg in both animals. Before, during and for 14 days after the course of drug administration both animals were assessed on several motor function tests. The animal receiving the small dose regime showed normal motor performance on all tests for the duration of the study, however, the monkey receiving the large dose regime displayed progressive akinesia, muscular rigidity and aphagia. In fact, impairment was so severe that this animal had to be force fed and maintained with daily oral L-dopa. Fluorescent histochemical assessment of forebrain in both monkeys revealed that striatal tissue was totally devoid of fluorescence in both cases. Large, swollen axons in the internal capsule, hypothalamus and midbrain were visible only in the severely impaired animal. These results suggest that, as with other neurotoxins, degeneration associated increases in amines may be important in the aetiology of Parkinson-like motor impairment produced by selective neurotoxins.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.